Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism

Neuropharmacology

Volumn 55, Issue 8, 2008, Pages 1340-1346

  Abdin, Amany A ^a   Hamouda, Hala E ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Apoptosis; Bcl 2; Coenzyme Q10; Levodopa; Mitochondrial dysfunction; Parkinsonism

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBIDOPA PLUS LEVODOPA; PROTEIN BCL 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; BRAIN MITOCHONDRION; BRAIN SLICE; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; DRUG MEGADOSE; LOW DRUG DOSE; MUSCLE RIGIDITY; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; LEVODOPA; MITOCHONDRIA; NAD; NEURONS; PARKINSONIAN DISORDERS; PROTO-ONCOGENE PROTEINS C-BCL-2; PSYCHOMOTOR PERFORMANCE; RATS; ROTENONE; SPECTROPHOTOMETRY; UBIQUINONE; VITAMINS;

EID: 56249128541     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2008.08.033     Document Type: Article

References (58)

1. Adams H. Adenosine 5-triphosphate determination with phosphoglycerate kinase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1963), Academic Press, New York 539-543
2. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 1 (2002) 317-324
3. Alam M., and Schmidt W.J. L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats. Behav. Brain Res. 153 2 (2004) 439-446
4. Anglade P., Vyas S., Javoy-Agid F., Herrero M.T., Michel P.P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E.C., and Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12 (1997) 25-31
5. Beal M.F., and Matthews R.S. Coenzyme Ql0 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol. Aspects Med. 18 Suppl. (1997) s169-s179
6. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 12 (2000) 1301-1306
7. Bhagavan H.N., and Chopra R.K. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 7 Suppl. (2007) S78-S88
8. Birch-Machin M.A., Briggs H.L., Saborido A.A., Bindoff L.A., and Turnbull D.M. An evaluation of the measurement of the activities of complexes I-IV in the respiratory chain of human skeletal muscle mitochondria. Biochem. Med. Metab. Biol. 51 1 (1994) 35-42
9. Blandini F., Cosentino M., Mangiagalli A., Marino F., Samuele A., Rasini E., Fancellu R., Tassorelli C., Pacchetti C., Martignoni E., Riboldazzi G., Calandrella D., Lecchini S., Frigo G., and Nappi G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 111 8 (2004) 1017-1030
10. Bonakdar R.A., and Guarneri E. Coenzyme Q10. Am. Fam. Physician 72 (2005) 1065-1070
11. Chen D.F., Schneider G.E., Martinou J.-C., and Tonegawa S. Bcl-2 promotes regeneration of severed axons in mammalian CNS. Nature 385 (1997) 434-439
12. Ciarolone A.E. Further modification of a fluorometric method for analyzing brain amines. Microchem. J. 23 (1978) 9-12
13. Clarke C.E., and Moore A.P. Parkinson's disease. Am. Fam. Physician 75 (2007) 1045-1048
14. Crane F.L. Biochemical functions of coenzyme Q10. J. Am. Coll. Nutr. 20 6 (2001) 591-598
15. Echtay K.S., Winkler E., and Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature 408 6812 (2000) 609-613
16. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., and Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U.S.A. 104 4 (2007) 1325-1330
17. Emdadul Haque M., Asanuma M., Higashi Y., Miyazaki I., Tanaka K., and Ogawa N. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim. Biophys. Acta 1619 1 (2003) 39-52
18. Fiskum G., Starkov A., Polster B.M., and Chinopoulos C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in parkinson's disease. Ann. N.Y. Acad. Sci. 991 (2003) 111-119
19. Hockenbery D.M., Oltvai Z.N., Yin X.M., Milliman C.L., and Korsmeyer S.J. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75 2 (1993) 241-251
20. Honda K., Tominaga S., Oshikata T., Kamiya K., Hamamura M., Kawasaki T., and Wakigawa K. Thirteen-week repeated dose oral toxicity study of coenzyme Q10 in rats. J. Toxicol. Sci. 32 4 (2007) 437-448
21. Ibrahim W.H., Bhagavan H.N., Chopra R.K., and Chow C.K. Dietary coenzyme Q10 and vitamin E alter the status of these compounds in rat tissues and mitochondria. J. Nutr. 130 (2000) 2343-2348
22. Jellinger K.A. Cell death mechanisms in Parkinson's disease. J. Neural Transm. 107 1 (2000) 1-29
23. Jimenez-Jimenez F.J., Molina J.A., De Bustos F., Garcia-Redondo A., Gomez-Escalonilla C., Martinez-Salio A., Berbel A., Camacho A., Zurdo M., Barcenilla B., Enriquez De Salamanca R., and Arenas J. Serum levels of coenzyme Q10 in patients with Parkinson's disease. J. Neural Transm. 107 2 (2000) 177-181
24. Karpińska J., Mikołuć B., and Piotrowska-Jastrzebska J. Application of derivative spectrophotometry for determination of coenzyme Q10 in pharmaceuticals and plasma. J. Pharm. Biomed. Anal. 17 8 (1998) 1345-1350
25. Kitamura Y., Kakimura J., and Taniguchi T. Antiparkinsonian drugs and their neuroprotective effects. Biol. Pharm. Bull. 25 3 (2002) 284-290
26. Kooncumchoo P., Sharma S., Porter J., Govitrapong P., and Ebadi M. Coenzyme Q(10) provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J. Mol. Neurosci. 28 2 (2006) 125-141
27. Kosel S., Egensperger R., von Eitzen U., Mehraein P., and Graeber M.B. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol. (Berl.) 93 (1997) 105-108
28. Kowaltowski A.J., Fenton R.G., and Fiskum G. Bcl-2 family proteins regulate mitochondrial reactive oxygen production and protect against oxidative stress. Free Radic. Biol. Med. 37 11 (2004) 1845-1853
29. Kwong L.K., Kamzalov S., Rebrin I., Bayne A.V., Jana C.K., Morris P., Forster M.J., and Sohal R.S. Effects of coenzyme Q10 administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic. Biol. Med. 33 5 (2002) 627-638
30. Lowry O.H., Rosebrough N.J., Farr A.I., and Randall R.J. Protein measurement with the Folin-Phenol reagent. J. Biol. Chem. 193 (1951) 265-275
31. Matthews R.T., Yang L., Browne S., Baik M., and Beal M.F. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U.S.A. 95 15 (1998) 8892-8897
32. Müller T., Büttner T., Gholipour A.F., and Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci. Lett. 341 3 (2003) 201-204
33. Muqit M.M., Gandhi S., and Wood N.W. Mitochondria in Parkinson disease: back in fashion with a little help from genetics. Arch. Neurol. 63 (2006) 649-654
34. Murphy A.N., Bredesen D.E., Cortopassi G., Wang E., and Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9893-9898
35. Naderi J., Somayajulu-Nitu M., Mukerji A., Sharda P., Sikorska M., Borowy-Borowski H., Antonsson B., and Pandey S. Water-soluble formulation of Coenzyme Q10 inhibits Bax-induced destabilization of mitochondria in mammalian cells. Apoptosis 11 8 (2006) 1359-1369
36. Pedrosa R., and Soares-da-Silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by l-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br. J. Pharmacol. 137 8 (2002) 1305-1313
37. Rachakonda V., Pan1 T.H., and Le W.D. Biomarkers of neurodegenerative disorders: how good are they?. Cell Res. 14 5 (2004) 349-360
38. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of parkinson disease: molecules to medicine. J. Clin. Invest. 116 (2006) 1744-1754
39. Scalori V., Alessandrì M.G., Mian M., Giovannini L., and Bertelli A.A. Plasma and tissue concentrations of coenzyme Q10 in the rat after its oral administration. Int. J. Tissue React. 10 2 (1988) 95-97
40. Schapira A.H.V., and Olanow C.W. Neuroprotection in parkinson disease. Mysteries, myths, and misconceptions. JAMA 291 (2004) 358-364
41. Schmidt W.J., and Alam M. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). J. Neural Transm. Suppl. 70 (2006) 273-276
42. Schuler F., and Casida J.E. Functional coupling of PSST and ND1 subunits in NADH:ubiquinone oxidoreductase established by photoaffinity labeling. Biochim. Biophys. Acta 1506 (2001) 79-87
43. Seyfried J., Evert B.O., Schwarz C.S., Schaupp M., Schulz J.B., Klockgether T., and Wüllner U. Gene dosage-dependent effects of bcl-2 expression on cellular survival and redox status. Free Radic. Biol. Med. 34 12 (2003) 1517-1530
44. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
45. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 34 (2003) 10756-10764
46. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., and Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59 10 (2002) 1541-1550
47. Shults C.W., Flint Beal M., Song D., and Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188 2 (2004) 491-494
48. Storch A., Jost W.H., Vieregge P., Spiegel J., Greulich W., Durner J., Müller T., Kupsch A., Henningsen H., Oertel W.H., Fuchs G., Kuhn W., Niklowitz P., Koch R., Herting B., and Reichmann H. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in parkinson disease. Arch. Neurol. 64 7 (2007) 938-944
49. Susin S.A., Zamzami N., Castedo M., Hirsch T., Marchetti P., Macho A., Daugas E., Geuskens M., and Kroemer G. Bcl-2 inhibits the mitochondrial release of an apoptogenic protease. J. Exp. Med. 184 4 (1996) 1331-1341
50. Talpade D.J., Greene J.G., Higgins Jr. D.S., and Greenamyre J.T. In vivo labeling of mitochondrial complex I (NADH:ubiquinone oxidoreductase) in rat brain using [(3)H]dihydrorotenone. J. Neurochem. 75 (2000) 2611-2621
51. Turpeenoja L., Villa R., Magri G., and Stella G. Changes of mitochondrial membrane proteins in rat cerebellum during aging. Neurochem. Res. 13 (1988) 859-865
52. Turunen M., Appelkvist E.L., Sindelar P., and Dallner G. Blood concentration of coenzyme Q10 increases in rats when esterified forms are administered. J. Nutr. 129 (1999) 2113-2118
53. Voehringer D.W. BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic. Biol. Med. 27 9-10 (1999) 945-950
54. Waldmeier P.C., and Tatton W.G. Interrupting apoptosis in neurodegenerative disease: potential for effective therapy?. Drug Discov. Today 9 5 (2004) 210-218
55. Yamada Y., Watanabe Y., Zhang J., Haraoka J., and Ito H. Changes in cortical and cerebellar bcl-2 mRNA levels in the developing hydrocephalic rat (LEW-HYR) as measured by a real time quantified RT-PCR. Neuroscience 114 1 (2002) 165-171
56. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., Peng T.I., Jones D.P., and Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 5303 (1997) 1129-1132
57. Yang L., Matthews R.T., Schulz J.B., Klockgether T., Liao A.W., Martinou J.C., Penney Jr. J.B., Hyman B.T., and Beal M.F. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J. Neurosci. 18 20 (1998) 8145-8152
58. Ziv I., Offen D., Barzilai A., Haviv R., Stein R., Zilkha-Falb R., Shirvan A., and Melamed E. Modulation of control mechanisms of dopamine-induced apoptosis-a future approach to the treatment of Parkinson's disease?. J. Neural Transm. Suppl. 49 (1997) 195-202